Home » News » New cancer vaccine being called a medical breakthrough

 In what is being called a medical breakthrough, a vaccine that targets skin cancer has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2. In what is being called a medical breakthrough, a vaccine that targets skin cancer has shown improved response rates and progression-free survival for patients when combined with the immunotherapy drug, Interleukin-2.

This new research was released today at the American Society of Clinical Oncology meeting in Orlando, Florida.  The breakthrough comes after three decades of failed attempts to produce cancer vaccines. The vaccine, developed by the National Cancer Institute (NCI) and called gp 100:209-217, or gp 100, helped shrink tumors as well as delay worsening of the disease in the study.

Vaccines work by training the body’s immune system to distinguish diseased cells and attack them. The hypothesis is that once the body can distinguish cancer cells, it can kill them before cancer has a opportunity to recur in a patient.

“Obviously, this is a disease, in its advanced setting, in need of better therapies for our patients,” said Hwu, a co-investigator on the study.

“While more follow up is needed, this study serves as a proof-of-principle for vaccines’ role in melanoma and in cancer therapy overall. If we can use the body’s own defense system to attack tumor cells, we provide a mechanism for ridding the body of cancer without destroying healthy tissue,” the expert added.

Approximately 22 percent of patients given the vaccine plus interleukin-2 saw their tumors shrink by half or more, compared with 10 percent of people getting interleukin-2 alone. Vaccine users saw their cancer stabilize for three months versus half that time for the others.

Melanoma is the most dangerous type of skin cancer. The five year-survival rates for local and metastatic melanoma are 65 percent and 16 percent, respectively. In 2009, an approximated 69,000 people in the U.S. will be diagnosed with melanoma and about 8,600 will die of the disease, according to the American Cancer Society.

2 Responses to “New cancer vaccine being called a medical breakthrough”

  1. I will be having surgery for skin cancer this month and have already had one surgery and radiation for a cancer in my throat.

    This article is of great importance to me as I have been having a running problem with skin cancer on my nose, probably developed from being on the golf course and not using sun screen.

    Sure would like to know if the vaccine will be available soon and if you can have it if you have already had cancer.

  2. Let me tell you - this stuff is for real. I was one of the test rats. In September 2006 I was diagnosed with Stage 3 B metastatic malignant melanoma. Prognosis was only 3 to 7 months. They put me in a Arizona Cancer Research trial. They took out a slew of lymph nodes and sent them to France and made a vaccine for me. They gave me 18 injections of the vaccine. It’s now 3 years and 6 months later and I’m still here to tell you about it. Keep the Faith.